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1. Introduction
This volume represents the second in a series of texts focused on extra-corporeal membrane 
oxygenation (ECMO), also known as extra-corporeal life support (ECLS) [1]. Over the years, 
there has been a continuous evolution of this therapy from a salvage form employed only 
in extreme cases in which all other treatment options have failed to a technology which is 
now considered a critical component in the toolbox of therapies and technologies used for 
acute cardiopulmonary failure. While initial experiences reported few survivors, these poor 
outcomes clearly had multifactorial etiologies [2]. Difficulties with primitive pump and cir-
cuit designs and technologies, a poor understanding of which patients derive the greatest 
benefit from this therapy, little understanding of the long-term physiologic implications of 
patient-circuit biologic interactions, a lack of management guidelines, and a generally limited 
understanding of managing patients and therapy-related complications while on “longer” 
term cardiopulmonary bypass have all contributed to the complexities of successful imple-
mentation of ECMO into mainstream medical and surgical practices. Nevertheless, over the 
past three decades, there has been continued refinement in all aspects of ECMO therapies, 
with a growing understanding of the role of ECMO as a life-saving therapy and potential 
bridge to transplantation while awaiting organ availability. ECMO has evolved into a treat-
ment option that allows for an acutely injured heart and or lungs to heal, either allowing 
for recovery or serving as a “bridge” to a more definitive long-term end-organ replacement 
option such as ventricular assist devices or cardiopulmonary transplantation [3]. Many of 
these complex topics are addressed in this contemporary volume. However, there remains, 
without a doubt, much more to learn and understand. The successes of the ECMO technology 
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reflect the tremendous efforts, dedication, and commitment by providers and researchers at 
all levels who recognize the enormous potential for ECMO to save lives and present options 
to those who would otherwise have none [4].
This volume reflects the substantial work of those, worldwide, who have dedicated a tremen-
dous amount of time and energy into better understanding of how to achieve better outcomes 
with this complex technology. The common theme of this work has been the recognition that 
teamwork is the most important variable that contributes to clinical success.
Developing a comprehensive “ECMO team” is one of the first steps in building a successful 
program. This team must be prepared to initiate therapy at any time and in any setting, from 
those as controlled as an operating room to those as chaotic as an emergency room. While 
the specific members of the team might vary from program to program, there are several 
key features that must be established in advance. It is well recognized that effective teams 
must communicate and work well together—there must be uniform trust and a collective 
value attached to the expertise that each member brings to the bedside. It likewise needs 
to be recognized that traditional medical and professional hierarchies might be considered 
“old-fashioned” and potentially ineffective, if not dangerous. Additionally, there must be a 
willingness to embrace the concepts of crew resource management (CRM). The foundation 
of CRM is that every member of the team has a voice and that each voice is valued and 
respected. All members of the team must be encouraged, if not empowered, to speak up, 
particularly when there are safety concerns. In the context of an ECMO team, membership 
must include all of the following related disciplines, including, but not limited to (and in no 
particular order of importance, as all are important):
• Surgeons (cardiothoracic, general, trauma, emergency medicine)
• Critical care intensivists (pulmonary, surgical)
• Medical specialists (infectious disease, neurology, cardiology)
• Perfusionists
• Pharmacists
• Nursing (bedside, advanced practice providers)
• Respiratory therapists
• Palliative care
• Hospital leadership and administration
• … and, most importantly, a Champion for the program to lead the team
As a function of the tremendous dedication of resources needed to establish a successful 
ECMO program, there must be a well-established network of support and encouragement 
from hospital administration and leadership (Figure 1) [5].
Increasingly, in medicine there is a recognition that optimal outcomes, especially with com-
plex and high-risk interventions, can be achieved using simulation training to help prepare 
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the team to respond in an effective and efficient manner. Especially in the case of time-
sensitive therapies such as ECMO, in which minutes sometimes can determine an outcome, 
simulation training must be a component of every program and practiced regularly. In addi-
tion, the equipment and team must be prepared to implement this therapy at any time with 
established protocols, guidelines, and goals of therapy [6]. The chapter by Dr. Sin Wai Ching 
emphasizes and outlines these topics.
While patient selection is a critical aspect of ECMO therapy, determining the type of therapy 
to initiate and how is likewise paramount. In the previous text, some of the topics related to 
cannulation techniques [7] and pump/circuit design and development were addressed [8]. 
The chapter by Borrelli further elaborates on these technical aspects of pump/circuit design by 
outlining their 23-year experience with pump positioning and holder systems.
Regarding the specifics of patient selection and implementing ECMO therapy, it is impor-
tant to understand how ECMO can (or should) be applied in specific clinical circumstances. 
Particularly, with regard to understanding the fundamental differences in veno-veno ECMO 
(VV-ECMO) for pulmonary support and veno-arterial ECMO (VA-ECMO) for cardiac or car-
diopulmonary support, several chapters discuss general clinical topics related to the specifics 
of therapy. These include chapters in cardiogenic shock, severe acute respiratory distress syn-
drome, and generalized applications for longer-term support. More focused topics include:
• Primary graft failure after heart transplantation (Caneo)
• Post-cardiotomy cardiogenic shock (Murashita)
• Unusual applications in the newborn (Wintermark)
• Applications and support in high-risk percutaneous cardiac interventions (Ganyukov)
Figure 1. ECMO “team.” Adopted from Reference intro chapter in Vol 1 (Ref [1]).
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It cannot be emphasized enough that a key component to a successful program is appropriate 
patient selection. Despite all of the advances in ECMO therapies over the years, even successful 
programs have outcomes that range from 60 to 70% survival for veno-veno pulmonary support 
and 25–35% for veno-arterial cardiopulmonary and emergent cardiopulmonary resuscitation 
applications (E-CPR) [9, 10]. Lower success rates that improve over time and with experience, 
improvements in institutional protocols, and better (and more-timely) patient selection can 
be expected during the early phases of program development. Alternatively, as is seen with 
other areas of innovative clinical therapies, programmatic successes and improving outcomes 
spur attempts at treating higher-risk patients, resulting in a paradoxical loss in these suc-
cesses. Programs with inordinately high success rates may be depriving salvageable patients 
the opportunity for survival because their indications are slightly out of the boundaries of 
the traditional indications for therapy. Programmatic attempts to support lower-risk patients 
on ECMO are not uncommon and are typically based on institutional (and personal) biases 
and outcomes. A series of successes with low-risk patients then rationalizes attempts to sal-
vage the higher-risk patient. Conversely, lower than desired outcomes in higher-risk patients 
might then limit selection back to patients with low-risk characteristics. Regardless, institu-
tional checks and balances as well as systems for reviewing metrics (clinical and financial) and 
outcomes should be established. Team engagement at all levels—from bedside nursing to top 
administrative leadership—is critical and cannot be emphasized enough. Membership and 
participation in the Extra-Corporeal Life Support Organization (ELSO: https://www.elso.org) 
should be encouraged, as it can provide data to help benchmark institutional success. 
Membership can also provide a community in which to partner with colleagues, exchange 
ideas, and as a resource for timely and important developments in the field.
Unusual patient populations represent one of the most rapidly expanding populations for 
ECMO. For example, early experiences with ECMO to support overwhelming septic shock 
in the setting of necrotizing soft tissues infections and the long-term, albeit anecdotal, good 
outcomes in this clinical scenario have prompted greater enthusiasm for otherwise potentially 
“hopeless” cases [11, 12]. There is also growing evidence supporting the role of ECMO to 
support high-risk catheter-based interventions, as discussed in the chapter by Dr. Ganyukov 
and colleagues [13]. However, such applications are limited to high-risk procedures in the 
catheterization laboratory, defined as those with impaired ventricular function and complex 
anatomy, or to reduce the risk of inherently high-risk or complex interventions, such as per-
cutaneous aortic valve procedures (i.e., transcatheter aortic valve replacement), coronary 
or cardiac structural interventions, or electrophysiologic ablative procedures for complex 
arrhythmias. The key goal of providing ECMO support during these procedures is to reduce 
the risks of end-organ dysfunction. Hemodynamic instability (or even acute failure) during 
such procedures could be reduced by using ECMO to provide support for brief periods of 
time until the pathology is corrected (i.e., the coronary artery is stented or valve dilated) [14].
Managing patients on ECMO represents one of the greatest clinical challenges in all of medi-
cine. Management on ECMO can be divided into several areas, and management decisions 
must be made in the context of the complex limitations of caring for patients on ECMO. For 
example, in many areas, there are little, if any, randomized evidence, established protocols, 
or even well-developed guidelines. Even simple interventions, like transporting patients on 
ECMO, require team-based decision-making regarding the potential risks and benefits [15]. 
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Nevertheless, there are growing data to support some of the challenging aspects of caring for 
ECMO patients. Some of these topics, while discussed in the first volume [1], are expounded 
upon in this text. Such examples include chapters on flow optimization and reduction of 
ventricular distention by Dr. Amarelli and the application and role of modified ultrafiltration 
in pediatric patients by Curi-Curi and colleagues.
As with any intervention on complex and high-risk patients, transparent, frequent, and hon-
est updates and communications with the family are critical to managing expectations. It 
is always important to emphasize that all communications should focus on the reality that 
even in ideal circumstances, morbidity and mortality in patients needing ECMO continue 
to be high. However, despite potentially long post-ECMO hospitalizations and recoveries, 
survivors can potentially return to productive lives [6].
2. Conclusions
The goal of this text is to demonstrate further that ECMO continues to evolve as a mainstream 
therapy for patients experiencing acute, severe, medically refractory cardiac and/or pulmonary 
Figure 2. BH (center in wheelchair) with his parents after qualifying for the finals in the single-scull, arms and shoulder 
only, rowing competition in the 2016 Paralympics in Rio de Janeiro. BH, a five-time USA national champion in the 
event, represented the USA in Rio as a member of the Olympic team. In 2016 he was elected US Rowing “Rower of 
the Year”. Several years prior, BH lost both legs to complications of a necrotizing soft tissue infection and required 
cardiopulmonary support with veno-arterial ECMO due to overwhelming septic shock. Picture used by permission by 
all represented [11, 12].
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failure. Contemporary trials continue to define the role of ECMO as the search for better out-
comes evolve [16]. However, as technology improves, guidelines get developed, protocols get 
refined, and experience grows, without a doubt, outcomes will improve [17]. ECMO, as a func-
tion of its invasiveness, need for substantial resources, and high-risk/high-reward, and novel 
technologies (i.e., the pump and oxygenators) often generates much institutional interest and 
intrigue. Unfortunately, many patients, despite such heroic efforts, die on ECMO—even when 
everything appears to have been done “right.” As important as it is to learn from all outcomes, 
it is critical that everyone cherishes all victories. Victories can inspire, give hope, and motivate 
a team even when further treatments appear futile (Figure 2). Even though there is still much 
to learn on the topic of ECMO, the goal of this text is to continue to build on the growing 
foundation of experiences and the current literature. If nothing else, the hope is to help inspire 
those intrigued by and who believe in the potential benefits of ECMO [18].
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